Table 5.
Per-protocol summary of month 7 anti-HPV geometric mean titers by region in women 16–26 years of age who received 3 doses of 9vHPV vaccine.
|
Region |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Africa |
Asia-Pacific |
Europe |
Latin America |
North America |
||||||
| Assay | n | GMT (95% CI) | n | GMT (95% CI) | n | GMT (95% CI) | n | GMT (95% CI) | n | GMT (95% CI) |
| HPV 6 | 16 | 1029.5 (708.5, 1496.1) |
691 | 817.9 (772.7, 865.8) |
1454 | 850.9 (818.2, 884.9) |
1292 | 946.6 (908.1, 986.8) |
868 | 953.2 (906.1, 1002.8) |
| HPV 11 | 15 | 764.4 (511.2, 1142.9) |
692 | 588.9 (555.0, 624.8) |
1458 | 660.0 (633.7, 687.5) |
1292 | 686.0 (656.9, 716.4) |
870 | 729.5 (692.0, 769.1) |
| HPV 16 | 20 | 5218.2 (3746.9, 7267.3) |
722 | 2943.1 (2785.2, 3109.8) |
1412 | 2929.3 (2816.1, 3047.1) |
1336 | 3355.0 (3221.8, 3493.8) |
871 | 3412.8 (3245.7, 3588.5) |
| HPV 18 | 21 | 1376.9 (930.3, 2037.7) |
758 | 827.4 (775.1, 883.2) |
1604 | 714.2 (682.9, 747.0) |
1537 | 887.6 (847.9, 929.2) |
964 | 838.4 (791.3, 888.3) |
| HPV 31 | 23 | 986.1 (673.5, 1443.9) |
785 | 673.6 (631.0, 719.0) |
1584 | 578.7 (552.7, 605.9) |
1454 | 725.5 (691.6, 761.2) |
960 | 717.3 (676.1, 760.9) |
| HPV 33 | 18 | 442.9 (300.3, 653.3) |
782 | 407.1 (383.8, 431.9) |
1635 | 396.9 (381.1, 413.4) |
1616 | 429.3 (412.0, 447.3) |
1005 | 450.9 (428.1, 475.0) |
| HPV 45 | 24 | 518.1 (343.1, 782.3) |
810 | 267.7 (249.4, 287.4) |
1714 | 207.8 (197.9, 218.2) |
1604 | 291.0 (276.7, 306.1) |
1008 | 272.0 (255.2, 289.8) |
| HPV 52 | 20 | 552.8 (376.5, 811.7) |
717 | 340.6 (319.4, 363.2) |
1620 | 365.1 (349.8, 381.0) |
1465 | 390.8 (373.7, 408.8) |
970 | 432.1 (409.0, 456.7) |
| HPV 58 | 15 | 706.9 (458.1, 1090.8) |
743 | 497.3 (467.5, 528.9) |
1647 | 468.2 (449.2, 487.9) |
1425 | 482.8 (461.7, 504.7) |
988 | 527.2 (499.8, 556.1) |
GMT, geometric mean titer (given in milli-Merck units per milliliter). CI, confidence interval.